bioAffinity Technologies, Inc. (NASDAQ:BIAF) — Market Cap & Net Worth
Market Cap & Net Worth: bioAffinity Technologies, Inc. (BIAF)
bioAffinity Technologies, Inc. (NASDAQ:BIAF) has a market capitalization of $3.77 Million ($3.77 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29086 globally and #5884 in its home market, demonstrating a -44.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying bioAffinity Technologies, Inc.'s stock price $0.84 by its total outstanding shares 4498675 (4.50 Million). Review BIAF liabilities breakdown to assess the company's total debt and financial obligations.
bioAffinity Technologies, Inc. Market Cap History: 2022 to 2026
bioAffinity Technologies, Inc.'s market capitalization history from 2022 to 2026. Data shows change from $7.20 Million to $3.77 Million (-45.34% CAGR).
Index Memberships
bioAffinity Technologies, Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #865 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #2737 of 3165 |
Weight: bioAffinity Technologies, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
bioAffinity Technologies, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how bioAffinity Technologies, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.86x
bioAffinity Technologies, Inc.'s market cap is 0.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $7.20 Million | $4.80K | -$8.15 Million | 1498.62x | N/A |
| 2023 | $6.62 Million | $2.53 Million | -$7.94 Million | 2.61x | N/A |
| 2024 | $4.09 Million | $9.36 Million | -$9.04 Million | 0.44x | N/A |
| 2025 | $5.31 Million | $6.16 Million | -$14.91 Million | 0.86x | N/A |
Competitor Companies of BIAF by Market Capitalization
Companies near bioAffinity Technologies, Inc. in the global market cap rankings as of June 19, 2026.
Key companies related to bioAffinity Technologies, Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
bioAffinity Technologies, Inc. Historical Marketcap From 2022 to 2026
Between 2022 and today, bioAffinity Technologies, Inc.'s market cap moved from $7.20 Million to $ 3.77 Million, with a yearly change of -45.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.77 Million | -29.05% |
| 2025 | $5.31 Million | +29.67% |
| 2024 | $4.09 Million | -38.12% |
| 2023 | $6.62 Million | -8.09% |
| 2022 | $7.20 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of bioAffinity Technologies, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.77 Million USD |
| MoneyControl | $3.77 Million USD |
| MarketWatch | $3.77 Million USD |
| marketcap.company | $3.77 Million USD |
| Reuters | $3.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more